Luigi Moretti

ORCID: 0009-0002-6180-0565
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chemical Reactions and Isotopes
  • PARP inhibition in cancer therapy
  • Endoplasmic Reticulum Stress and Disease
  • Advances in Oncology and Radiotherapy
  • Lung Cancer Diagnosis and Treatment
  • Cell death mechanisms and regulation
  • ATP Synthase and ATPases Research
  • Cancer Immunotherapy and Biomarkers
  • Global Cancer Incidence and Screening
  • Chronic Disease Management Strategies
  • Radiomics and Machine Learning in Medical Imaging
  • Acute Myocardial Infarction Research
  • Retinal Imaging and Analysis
  • Cerebrovascular and Carotid Artery Diseases
  • Cardiovascular Function and Risk Factors
  • Neuroblastoma Research and Treatments
  • Cancer survivorship and care
  • Colorectal Cancer Surgical Treatments
  • Palliative Care and End-of-Life Issues
  • Clinical practice guidelines implementation
  • Health and Medical Research Impacts
  • Adrenal Hormones and Disorders
  • Health Promotion and Cardiovascular Prevention
  • Lung Cancer Treatments and Mutations
  • Cardiac Imaging and Diagnostics

Institut Jules Bordet
2014-2024

Université Libre de Bruxelles
2014-2024

University of Bari Aldo Moro
2022

Institute of Neurological Sciences
1985

University of Siena
1985

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest tumors with slow progress in systemic therapies due to its peculiar and resistant tumor microenvironment. Inclusion isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) into a total neoadjuvant strategy (TNT) is promising for treatment localized PDAC. However, histo-molecular effects iHD-SBRT are still poorly explored. In this study, we have shown that TNT, associating FOLFIRINOX [FFX] followed by iHD-SBRT,...

10.1101/2024.04.30.591890 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2024-05-03

Immune checkpoint inhibitors and immune-related biomarkers are increasingly investigated in rectal cancer (RC). We retrospectively analysed PD-L1 expression diagnostic biopsy resection samples from RC patients treated at our centre between 2000 2020. immunostaining (22C3 clone) was evaluated according to tumour proportion (TPS), immune cell (ICS), the combined positive score (CPS). Eighty-three were included. At diagnosis, ≥1%/≥5% observed 15.4%/0%, 80.7%/37.4%, 69.2%/25.6% of based on TPS,...

10.3390/cancers16142606 article EN Cancers 2024-07-21

Abstract Corticosteroids play an important role in clinical oncology, and they may be used alone or combination with other treatments the therapy of cancer patients. Commonly to decrease inflammations. In this overview, by discussions on applications corticosteroids that are mainly we suggest careful use is required balance between risks benefits should always considered oncology.

10.4103/2224-4018.135608 article EN cc-by-nc-nd Journal of Translational Internal Medicine 2014-06-01

Retinal fluorangiographic techniques can be employed in the study of cerebrovascular disorders relation to embryological, anatomic and functional affinities between cerebral retinal circulation. The currently used have been improved by means computer analysis photographic image, thus allowing qualitative evaluations vascular dynamics quantitative referred remarkable variations. These summed up as follows: equidensitometry with arbitrary colors, computerized fluorangiography for evaluation...

10.1177/03331024850050s210 article EN Cephalalgia 1985-05-01

Supplementary Fig. S2 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor

10.1158/1535-7163.22485629.v1 preprint EN cc-by 2023-03-31

Supplementary Fig. S1 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor

10.1158/1535-7163.22485632.v1 preprint EN cc-by 2023-03-31

<div>Abstract<p>Despite recent advances in the management of breast and lung cancer, novel treatment strategies are still needed to further improve patient outcome. The targeting cell death pathways has therefore been proposed enhance therapeutic ratio cancer. In this study, we examined <i>in vitro</i> vivo</i> effects Z-VAD, a broad-spectrum caspase inhibitor, on cancer association with radiation. Using clonogenic assays, observed that Z-VAD markedly...

10.1158/1535-7163.c.6532034 preprint EN 2023-03-31

<div>Abstract<p>Despite recent advances in the management of breast and lung cancer, novel treatment strategies are still needed to further improve patient outcome. The targeting cell death pathways has therefore been proposed enhance therapeutic ratio cancer. In this study, we examined <i>in vitro</i> vivo</i> effects Z-VAD, a broad-spectrum caspase inhibitor, on cancer association with radiation. Using clonogenic assays, observed that Z-VAD markedly...

10.1158/1535-7163.c.6532034.v1 preprint EN 2023-03-31

Supplementary Fig. S1 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor

10.1158/1535-7163.22485632 preprint EN cc-by 2023-03-31

Supplementary Fig. S2 from Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor

10.1158/1535-7163.22485629 preprint EN cc-by 2023-03-31

Background and Objective: Quality of treatment planning delivery in radiation oncology is crucial.To tackle inter-operator variability (IOV), peer review quality assurance (PRQA) has been increasingly implemented over the past decades become part standard clinical practice, through recommendations multiple national regional guidelines.In context ongoing ProCaLung (PROject on CAncer LUNG) initiative Belgium, an assessment current practice proposed here.The main aims are to identify frequency...

10.21037/pcm-22-17 article EN cc-by-nc-nd Precision Cancer Medicine 2022-09-02
Coming Soon ...